- Fakih, M., Chen, E. X., Lee, K.-W., Bekaii-Saab, T. S., Lonardi, S., Gong, J., Elez, E., Lau, J., Breton, V., Khan, O., Chertkova, O., Jain, S., & Han, S.-W. (2026). Phase I/Ib study of inavolisib (Inavo) + bevacizumab (Bev) or cetuximab (Cetux) for PIK3CA -mutated (Mut) metastatic colorectal cancer (Mcrc). Journal of Clinical Oncology, 44(2_suppl), 158-158. https://doi.org/10.1200/JCO.2026.44.2_suppl.158 (Meeting abstract)
Phase I/Ib study of inavolisib (Inavo) + bevacizumab (Bev) or cetuximab (Cetux) for PIK3CA -mutated (Mut) metastatic colorectal cancer (Mcrc)
on 8 de juny de 2026
with No hi ha comentaris
Deixa un comentari